These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18812542)

  • 1. ESAs further restricted, but debate continues.
    Brower V
    J Natl Cancer Inst; 2008 Oct; 100(19):1344-51. PubMed ID: 18812542
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA finalizes REMS program for ESAs; Amgen continues to study risks.
    Brower V
    J Natl Cancer Inst; 2010 May; 102(9):592-3. PubMed ID: 20421565
    [No Abstract]   [Full Text] [Related]  

  • 3. New ASH/ASCO guidelines on the use of erythropoiesis-stimulating agents: a chorale amid cacophony.
    Steensma DP
    J Support Oncol; 2007; 5(10):471-3. PubMed ID: 18240668
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety concerns for two big anemia drugs.
    Nursing; 2008 Oct; 38(10):12. PubMed ID: 18812980
    [No Abstract]   [Full Text] [Related]  

  • 5. The FDA, stocks, black boxes and ESAs.
    Spry L
    Nephrol News Issues; 2007 May; 21(6):53-4. PubMed ID: 17518124
    [No Abstract]   [Full Text] [Related]  

  • 6. Erythropoietin, the FDA, and oncology.
    Steinbrook R
    N Engl J Med; 2007 Jun; 356(24):2448-51. PubMed ID: 17568025
    [No Abstract]   [Full Text] [Related]  

  • 7. New oversight put in place for physicians giving anemia drugs to patients with cancer.
    Mitka M
    JAMA; 2010 Apr; 303(14):1355-6. PubMed ID: 20388885
    [No Abstract]   [Full Text] [Related]  

  • 8. Weighing the hazards of erythropoiesis stimulation in patients with cancer.
    Khuri FR
    N Engl J Med; 2007 Jun; 356(24):2445-8. PubMed ID: 17568023
    [No Abstract]   [Full Text] [Related]  

  • 9. Erythropoietin: high profile, high scrutiny.
    Crawford J
    J Clin Oncol; 2007 Mar; 25(9):1021-3. PubMed ID: 17312331
    [No Abstract]   [Full Text] [Related]  

  • 10. Rebates for anti-anemia drugs draw response from FDA, CMS.
    Sipkoff M
    Manag Care; 2007 Jun; 16(6):17-8. PubMed ID: 17682732
    [No Abstract]   [Full Text] [Related]  

  • 11. Darbepoetin alfa in the treatment of anemia in cancer patients undergoing chemotherapy.
    Wauters I; Vansteenkiste J
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1383-90. PubMed ID: 23113603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor progression associated with erythropoiesis-stimulating agents.
    Newland AM; Black CD
    Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin: the swinging pendulum.
    Oster HS; Neumann D; Hoffman M; Mittelman M
    Leuk Res; 2012 Aug; 36(8):939-44. PubMed ID: 22579365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thromboembolic events and erythropoiesis-stimulating agents: an update.
    Dicato M
    Oncologist; 2008; 13 Suppl 3():11-5. PubMed ID: 18458119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoietins should be used according to guidelines.
    Aapro MS; Birgegård G; Bokemeyer C; Cornes P; Foubert J; Gascon P; Glaspy J; Hellström-Lindberg E; Link H; Ludwig H; Osterborg A; Repetto L; Soubeyran P
    Lancet Oncol; 2008 May; 9(5):412-3. PubMed ID: 18452853
    [No Abstract]   [Full Text] [Related]  

  • 16. The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced anemia.
    Boccia R; Lillie T; Tomita D; Balducci L
    Oncologist; 2007 May; 12(5):584-93. PubMed ID: 17522247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reevaluating erythropoiesis-stimulating agents.
    Cotter DJ
    N Engl J Med; 2010 May; 362(18):1743; author reply 1743-4. PubMed ID: 20449881
    [No Abstract]   [Full Text] [Related]  

  • 18. FDA panel scrutinizes safety of anti-anemia drugs.
    Randal J
    J Natl Cancer Inst; 2004 Jul; 96(14):1061. PubMed ID: 15265966
    [No Abstract]   [Full Text] [Related]  

  • 19. Epoetin versus darbepoetin conundrum compromise.
    Bleyer A
    J Clin Oncol; 2006 Sep; 24(25):e46. PubMed ID: 16943519
    [No Abstract]   [Full Text] [Related]  

  • 20. Cancer-related anaemia management in the 21st century.
    Pronzato P
    Cancer Treat Rev; 2006; 32 Suppl 2():S1-3. PubMed ID: 16725269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.